Description

ANGISPAN TR 6.5 MG (1X30)

Indications

ANGISPAN TR 6.5 MG is primarily indicated for the management of angina pectoris, a condition characterized by chest pain due to insufficient blood flow to the heart muscle. This medication is beneficial for patients experiencing stable angina, as it helps to alleviate symptoms and improve overall heart function. Additionally, it may be utilized in certain cases of hypertension, where it aids in the reduction of elevated blood pressure levels, thereby decreasing the risk of cardiovascular events.

Mechanism of Action

The active ingredient in ANGISPAN TR is isosorbide mononitrate, a nitrate that works by relaxing the smooth muscles of blood vessels. This vasodilation effect leads to an increase in blood flow to the heart, reducing the workload on the heart and alleviating angina symptoms. By decreasing myocardial oxygen demand and improving oxygen delivery, ANGISPAN TR effectively manages angina episodes and enhances exercise tolerance in patients.

Pharmacological Properties

ANGISPAN TR exhibits a prolonged release formulation, allowing for sustained therapeutic effects over an extended period. The pharmacokinetics of isosorbide mononitrate indicate that it has a peak plasma concentration reached within 1 to 2 hours after administration. The drug has a half-life of approximately 5 hours, which supports its dosing schedule. Isosorbide mononitrate is metabolized in the liver and excreted primarily through the kidneys, necessitating caution in patients with renal impairment.

Contraindications

ANGISPAN TR is contraindicated in patients with known hypersensitivity to isosorbide mononitrate or any of its excipients. It should not be used in individuals who are concurrently taking phosphodiesterase inhibitors, such as sildenafil, due to the risk of severe hypotension. Additionally, it is contraindicated in patients with severe anemia, closed-angle glaucoma, and those with a history of hypotensive episodes or shock.

Side Effects

Common side effects associated with ANGISPAN TR include headache, dizziness, and flushing, which are typically related to its vasodilatory effects. Other potential side effects may include hypotension, tachycardia, and gastrointestinal disturbances such as nausea or vomiting. Serious adverse reactions, although rare, may include severe allergic reactions, syncope, or myocardial infarction in patients with underlying cardiovascular conditions. Patients should be advised to report any unusual or severe symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of ANGISPAN TR for adults is typically one tablet of 6.5 mg taken orally once daily, preferably in the morning to minimize the risk of tolerance development. It is crucial to swallow the tablet whole with a glass of water and not to crush or chew it, as this may affect the sustained-release properties. Dosage adjustments may be necessary for elderly patients or those with renal impairment, and it is advisable to follow a healthcare provider’s instructions regarding any modifications.

Interactions

ANGISPAN TR may interact with various medications, leading to enhanced hypotensive effects. Caution should be exercised when used in conjunction with other antihypertensive agents, diuretics, or alcohol, as these can potentiate the blood pressure-lowering effects. Additionally, concurrent use with phosphodiesterase inhibitors can lead to life-threatening hypotension. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are currently taking to avoid potential interactions.

Precautions

Before initiating treatment with ANGISPAN TR, a comprehensive medical history should be taken to identify any pre-existing conditions that may contraindicate its use. Special caution is warranted in patients with a history of myocardial infarction, congestive heart failure, or those with significant hepatic or renal impairment. It is essential to monitor blood pressure regularly during treatment, especially in patients with a history of hypotension. Patients should also be advised to avoid activities requiring mental alertness until they understand how ANGISPAN TR affects them.

Clinical Studies

Clinical studies have demonstrated the efficacy of isosorbide mononitrate in reducing the frequency and severity of angina episodes. In a randomized controlled trial, patients receiving ANGISPAN TR reported a significant improvement in exercise tolerance and a reduction in angina attacks compared to those receiving placebo. Furthermore, studies have indicated that the sustained-release formulation provides a more consistent therapeutic effect, allowing for better management of chronic angina symptoms over time. Ongoing research continues to explore the long-term benefits and safety profile of ANGISPAN TR in diverse patient populations.

Conclusion

ANGISPAN TR 6.5 MG is an effective medication for the management of angina pectoris and hypertension. Its mechanism of action as a vasodilator helps to alleviate symptoms and improve quality of life for patients suffering from these conditions. While generally well-tolerated, it is essential for patients to be aware of potential side effects, contraindications, and drug interactions. Regular monitoring and communication with healthcare providers will ensure the safe and effective use of ANGISPAN TR, contributing to better cardiovascular health outcomes.